Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data

Dongshan Zhu, Hsin-Fang Chung, Annette J Dobson, Nirmala Pandeya, Graham G Giles, Fiona Bruinsma, Eric J Brunner, Diana Kuh, Rebecca Hardy, Nancy E Avis, Ellen B Gold, Carol A Derby, Karen A Matthews, Janet E Cade, Darren C Greenwood, Panayotes Demakakos, Daniel E Brown, Lynnette L Sievert, Debra Anderson, Kunihiko Hayashi, Jung Su Lee, Hideki Mizunuma, Therese Tillin, Mette Kildevæld Simonsen, Hans-Olov Adami, Elisabete Weiderpass, Gita D Mishra, Dongshan Zhu, Hsin-Fang Chung, Annette J Dobson, Nirmala Pandeya, Graham G Giles, Fiona Bruinsma, Eric J Brunner, Diana Kuh, Rebecca Hardy, Nancy E Avis, Ellen B Gold, Carol A Derby, Karen A Matthews, Janet E Cade, Darren C Greenwood, Panayotes Demakakos, Daniel E Brown, Lynnette L Sievert, Debra Anderson, Kunihiko Hayashi, Jung Su Lee, Hideki Mizunuma, Therese Tillin, Mette Kildevæld Simonsen, Hans-Olov Adami, Elisabete Weiderpass, Gita D Mishra

Abstract

Background: Early menopause is linked to an increased risk of cardiovascular disease mortality; however, the association between early menopause and incidence and timing of cardiovascular disease is unclear. We aimed to assess the associations between age at natural menopause and incidence and timing of cardiovascular disease.

Methods: We harmonised and pooled individual-level data from 15 observational studies done across five countries and regions (Australia, Scandinavia, the USA, Japan, and the UK) between 1946 and 2013. Women who had reported their menopause status, age at natural menopause (if postmenopausal), and cardiovascular disease status (including coronary heart disease and stroke) were included. We excluded women who had hysterectomy or oophorectomy and women who did not report their age at menopause. The primary endpoint of this study was the occurrence of first non-fatal cardiovascular disease, defined as a composite outcome of incident coronary heart disease (including heart attack and angina) or stroke (including ischaemic stroke or haemorrhagic stroke). We used Cox proportional hazards models to estimate multivariate hazard ratios (HRs) and 95% CIs for the associations between age at menopause and incident cardiovascular disease event. We also adjusted the model to account for smoking status, menopausal hormone therapy status, body-mass index, and education levels. Age at natural menopause was categorised as premenopausal or perimenopausal, younger than 40 years (premature menopause), 40-44 years (early menopause), 45-49 years (relatively early), 50-51 years (reference category), 52-54 years (relatively late), and 55 years or older (late menopause).

Findings: Overall, 301 438 women were included in our analysis. Of these 301 438 women, 12 962 (4·3%) had a first non-fatal cardiovascular disease event after menopause, of whom 9369 (3·1%) had coronary heart disease and 4338 (1·4%) had strokes. Compared with women who had menopause at age 50-51 years, the risk of cardiovascular disease was higher in women who had premature menopause (age <40 years; HR 1·55, 95% CI 1·38-1·73; p<0·0001), early menopause (age 40-44 years; 1·30, 1·22-1·39; p<0·0001), and relatively early menopause (age 45-49 years; 1·12, 1·07-1·18; p<0·0001), with a significantly reduced risk of cardiovascular disease following menopause after age 51 years (p<0·0001 for trend). The associations persisted in never smokers, and were strongest before age 60 years for women with premature menopause (HR 1·88, 1·62-2·20; p<0·0001) and early menopause (1·40, 1·27-1·54; p<0·0001), but were attenuated at age 60-69 years, with no significant association observed at age 70 years and older.

Interpretation: Compared with women who had menopause at age 50-51 years, women with premature and early menopause had a substantially increased risk of a non-fatal cardiovascular disease event before the age of 60 years, but not after age 70 years. Women with earlier menopause need close monitoring in clinical practice, and age at menopause might also be considered as an important factor in risk stratification of cardiovascular disease for women.

Funding: Australian National Health and Medical Research Council.

© 2019 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY NC ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. This article shall not be used or reproduced in association with the promotion of commercial products, services or any entity. There should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.

Figures

Figure 1
Figure 1
Association between age at natural menopause and first cardiovascular events Association between age at menopause and incident cardiovascular disease (A), coronary heart disease (B), and stroke (C). Restricted cubic spline models were used to visualise the shape. HR=hazard ratio.
Figure 2
Figure 2
Combined effect of age at menopause and menopausal hormone therapy on risk of incident cardiovascular disease, coronary heart disease, and stroke events Cox proportional hazards models were used to estimate HRs and 95% CIs. HRs were adjusted for age at last follow-up, ethnicity, education level, body-mass index, smoking status, and hypertension status. n=number of events. N=number of participants. HR=hazard ratio. MHT=menopausal hormone therapy.
Figure 3
Figure 3
Combined effect of age at menopause and smoking status on risk of incident cardiovascular disease, coronary heart disease, and stroke Cox proportional hazards models were used to estimate HRs and 95% CIs. All HRs were adjusted for age at last follow-up, ethnicity, education level, body-mass index, hypertension status, and postmenopausal menopausal hormone therapy status or oral contraception use in the premenopause or perimenopause group. n=number of events. N=number of participants. HR=hazard ratio.

References

    1. Nelson HD. Menopause. Lancet. 2008;371:760–770.
    1. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol. 2014;43:1542–1562.
    1. Gold EB, Crawford SL, Avis NE. Factors related to age at natural menopause: longitudinal analyses from SWAN. Am J Epidemiol. 2013;178:70–83.
    1. Gold EB, Bromberger J, Crawford S. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol. 2001;153:865–874.
    1. Santoro N. Mechanisms of premature ovarian failure. Ann Endocrinol. 2003;64:87–92.
    1. Shifren JL, Gass ML, NAMS Recommendations for Clinical Care of Midlife Women Working Group The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21:1038–1062.
    1. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003;18:199–206.
    1. Muka T, Oliver-Williams C, Kunutsor S. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1:767–776.
    1. Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am. 2011;38:425–440.
    1. Mishra GD, Anderson D, Schoenaker DA. InterLACE: a new International Collaboration for a Life Course Approach to Women's Reproductive Health and Chronic Disease Events. Maturitas. 2013;74:235–240.
    1. Mishra GD, Chung HF, Pandeya N. The InterLACE study: design, data harmonization and characteristics across 20 studies on women's health. Maturitas. 2016;92:176–185.
    1. Sudlow C, Gallacher J, Allen N. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12
    1. Zhu D, Chung HF, Pandeya N. Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: a pooled analysis of individual data from 17 observational studies. PLoS Med. 2018;15
    1. Zhu D, Chung HF, Pandeya N. Body mass index and age at natural menopause: an international pooled analysis of 11 prospective studies. Eur J Epidemiol. 2018;33:699–710.
    1. Lee C, Dobson AJ, Brown WJ. Cohort Profile: the Australian Longitudinal Study on Women's Health. Int J Epidemiol. 2005;34:987–991.
    1. Seib C, Whiteside E, Humphreys J. A longitudinal study of the impact of chronic psychological stress on health-related quality of life and clinical biomarkers: protocol for the Australian Healthy Aging of Women Study. BMC Public Health. 2014;14:9.
    1. Milne RL, Fletcher AS, MacInnis RJ. Cohort profile: the Melbourne Collaborative Cohort Study (Health 2020) Int J Epidemiol. 2017;46:1757–1778.
    1. Hundrup YA, Simonsen MK, Jorgensen T, Obel EB. Cohort profile: the Danish nurse cohort. Int J Epidemiol. 2012;41:1241–1247.
    1. Roswall N, Sandin S, Adami HO, Weiderpass E. Cohort profile: the Swedish Women's Lifestyle and Health cohort. Int J Epidemiol. 2017;46:e8.
    1. Sievert LL, Morrison LA, Reza AM, Brown DE, Kalua E, Tefft HA. Age-related differences in health complaints: the Hilo women's health study. Women Health. 2007;45:31–51.
    1. Sowers MFR, Crawford SL, Sternfeld B. SWAN: a multicenter, multiethnic, community-based cohort study of women and the menopausal transition. In: Lobo RAKJ, Marcus R, editors. Menopause: biology and pathobiology. 1st edn. Academic Press; New York: 2000. pp. 175–188.
    1. Hayashi K, Mizunuma H, Fujita T. Design of the Japan Nurses' Health Study: a prospective occupational cohort study of women's health in Japan. Ind Health. 2007;45:679–686.
    1. Wadsworth M, Kuh D, Richards M, Hardy R. Cohort profile: the 1946 National Birth Cohort (MRC National Survey of Health and Development) Int J Epidemiol. 2006;35:49–54.
    1. Power C, Elliott J. Cohort profile: 1958 british birth cohort (National Child Development Study) Int J Epidemiol. 2006;35:34–41.
    1. Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: the English longitudinal study of ageing. Int J Epidemiol. 2013;42:1640–1648.
    1. Cade JE, Burley VJ, Alwan NA. Cohort profile: the UK Women's Cohort Study (UKWCS) Int J Epidemiol. 2017;46:e11.
    1. Marmot M, Brunner E. Cohort profile: the Whitehall II study. Int J Epidemiol. 2005;34:251–256.
    1. Tillin T, Forouhi NG, McKeigue PM, Chaturvedi N, SABRE Study Group Southall And Brent REvisited: cohort profile of SABRE, a UK population-based comparison of cardiovascular disease and diabetes in people of European, Indian Asian and African Caribbean origins. Int J Epidemiol. 2012;41:33–42.
    1. Ley SH, Li Y, Tobias DK. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women. J Am Heart Assoc. 2017;6
    1. Ingelsson E, Lundholm C, Johansson AL, Altman D. Hysterectomy and risk of cardiovascular disease: a population-based cohort study. Eur Heart J. 2011;32:745–750.
    1. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet. 1998;351:1425–1427.
    1. Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause. 2012;19:1081–1087.
    1. Hu FB, Grodstein F, Hennekens CH. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med. 1999;159:1061–1066.
    1. Løkkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas. 2006;53:226–233.
    1. Shen L, Song L, Liu B. Effects of early age at natural menopause on coronary heart disease and stroke in Chinese women. Int J Cardiol. 2017;241:6–11.
    1. Dam V, van der Schouw YT, Onland-Moret NC. Association of menopausal characteristics and risk of coronary heart disease: a pan-European case-cohort analysis. Int J Epidemiol. 2019 doi: 10.1093/ije/dyz016. published online Feb 22.
    1. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.
    1. Lisabeth L, Bushnell C. Stroke risk in women: the role of menopause and hormone therapy. Lancet Neurol. 2012;11:82–91.
    1. Baba Y, Ishikawa S, Amagi Y, Kayaba K, Gotoh T, Kajii E. Premature menopause is associated with increased risk of cerebral infarction in Japanese women. Menopause. 2010;17:506–510.
    1. Choi SH, Lee S-M, Kim Y, Choi N-K, Cho YJ, Park B-J. Natural menopause and risk of stroke in elderly women. J Korean Med Sci. 2005;20:1053–1058.
    1. Lisabeth LD, Beiser AS, Brown DL, Murabito JM, Kelly-Hayes M, Wolf PA. Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke. 2009;40:1044–1049.
    1. Boardman HM, Hartley L, Eisinga A. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;3
    1. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996;347:714–718.
    1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–1811.
    1. Mazzuca MQ, Mata KM, Li W, Rangan SS, Khalil RA. Estrogen receptor subtypes mediate distinct microvascular dilation and reduction in [Ca2+]I in mesenteric microvessels of female rat. J Pharmacol Exp Ther. 2015;352:291–304.
    1. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther. 2012;135:54–70.
    1. Sutton-Tyrrell K, Wildman RP, Matthews KA. Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN) Circulation. 2005;111:1242–1249.
    1. Rexrode KM, Manson JE, Lee IM. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation. 2003;108:1688–1693.
    1. Zhu D, Chung HF, Pandeya N. Premenopausal cardiovascular disease and age at natural menopause: a pooled analysis of over 170,000 women. Eur J Epidemiol. 2019;34:235–246.
    1. Matthews KA, Crawford SL, Chae CU. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54:2366–2373.
    1. Kuh D, Langenberg C, Hardy R. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study. BJOG. 2005;112:476–485.
    1. Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause. 2011;18:1172–1177.
    1. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med. 2008;168:861–866.
    1. den Tonkelaar I. Validity and reproducibility of self-reported age at menopause in women participating in the DOM-project. Maturitas. 1997;27:117–123.
    1. Jorstad HT, Colkesen EB, Boekholdt SM. Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk. Heart. 2016;102:63–68.
    1. Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;22:403–411.
    1. Schneider HPG, Birkhauser M. Quality of life in climacteric women. Climacteric. 2017;20:187–194.
    1. GBD 2016 Neurology Collaborators Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459–480.
    1. Moran AE, Forouzanfar MH, Roth GA. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation. 2014;129:1493–1501.

Source: PubMed

3
購読する